Quantitative Eye Movement Measurements in Patients with Acute Vestibular Syndrome
Launched by ALEXANDER TARNUTZER · Oct 30, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how eye movements and pupil responses can help doctors better understand the causes of acute vestibular syndrome (AVS), which includes conditions like severe dizziness and vertigo. The goal is to find reliable tests that can quickly distinguish between more serious causes, like a stroke, and less serious ones. This is important because about 25% of patients with AVS have a stroke that is often missed during initial evaluations. By using special equipment and tests, the researchers hope to improve the accuracy of diagnoses for patients experiencing sudden dizziness.
To participate in the trial, individuals must be at least 18 years old and have experienced dizziness for 5 days or less, with the ability to undergo an MRI (a type of brain scan). Participants will undergo various eye movement tests and assessments to help researchers understand their condition better. This trial is not yet recruiting participants, but it aims to enhance how emergency departments evaluate and treat patients with dizziness, potentially leading to better outcomes and fewer misdiagnoses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient groups
- • patients presenting with an AVS (peripheral or central), with symptom duration of 5 days or less
- • being able to receive brain MRI
- * All groups:
- • Being able to give informed consent as documented by signature
- • Age 18 years or above
- Exclusion Criteria:
- • Aged less than 18 years.
- • Pregnant or lactating women
- • Inability or contraindications to undergo the investigated intervention (including brain MRI in the patient groups),
- • Clinically significant concomitant diseases such neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease)
- • Pre-existing peripheral-vestibular / central-vestibular deficits
- • History of brainstem / cerebellar stroke
- • Pre-existing or acute severe visual loss
- • Pre-existing severe hearing loss.
- • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, aphasia.
About Alexander Tarnutzer
Alexander Tarnutzer is a dedicated clinical trial sponsor with a focus on advancing medical research and improving patient outcomes. With a commitment to innovation and ethical standards, the organization collaborates with healthcare professionals and research institutions to conduct rigorous clinical studies across various therapeutic areas. Alexander Tarnutzer emphasizes transparency, patient safety, and compliance with regulatory guidelines, ensuring that all trials are designed and executed to the highest scientific and ethical standards. Through its efforts, the organization aims to contribute valuable insights to the medical community and drive the development of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Alexander A Tarnutzer, MD
Principal Investigator
Neurology, Cantonal Hospital of Baden, Baden, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported